146 related articles for article (PubMed ID: 10090788)
1. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.
Medhurst AD; Hay DW; Parsons AA; Martin LD; Griswold DE
Br J Pharmacol; 1997 Oct; 122(3):469-76. PubMed ID: 9351503
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Sarau HM; Griswold DE; Potts W; Foley JJ; Schmidt DB; Webb EF; Martin LD; Brawner ME; Elshourbagy NA; Medhurst AD; Giardina GA; Hay DW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1303-11. PubMed ID: 9190866
[TBL] [Abstract][Full Text] [Related]
7. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
[TBL] [Abstract][Full Text] [Related]
8. Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer.
Jordan RE; Smart D; Grimson P; Suman-Chauhan N; McKnight AT
Br J Pharmacol; 1998 Oct; 125(4):761-6. PubMed ID: 9831912
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
[TBL] [Abstract][Full Text] [Related]
10. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
11. Bronchoconstrictor effect of the tachykinin NK₃-receptor agonists [MePhe⁷]-neurokinin B and senktide in the isolated guinea pig lung.
Corboz MR; Rivelli MA; Eckel SP
Exp Lung Res; 2010 Nov; 36(9):509-21. PubMed ID: 20939761
[TBL] [Abstract][Full Text] [Related]
12. Characterization of NK3 receptors in rabbit isolated iris sphincter muscle.
Medhurst AD; Parsons AA; Roberts JC; Hay DW
Br J Pharmacol; 1997 Jan; 120(1):93-101. PubMed ID: 9117105
[TBL] [Abstract][Full Text] [Related]
13. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
14. Use of a dipeptide chemical library in the development of non-peptide tachykinin NK3 receptor selective antagonists.
Boden P; Eden JM; Hodgson J; Horwell DC; Hughes J; McKnight AT; Lewthwaite RA; Pritchard MC; Raphy J; Meecham K; Ratcliffe GS; Suman-Chauhan N; Woodruff GN
J Med Chem; 1996 Apr; 39(8):1664-75. PubMed ID: 8648606
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
16. Functionalization through lithiation of (S)-N-(1-phenylpropyl)-2-phenylquinoline-4-carboxamide. Application to the labeling with carbon-11 of NK-3 receptor antagonist SB 222200.
Bennacef I; Perrio C; Lasne MC; Barré L
J Org Chem; 2007 Mar; 72(6):2161-5. PubMed ID: 17319724
[TBL] [Abstract][Full Text] [Related]
17. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
Simmons MA; Sobotka-Briner CD; Medd AM
Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of senktide-induced tail whips.
Nordquist RE; Ballard TM; Algeyer B; Pauly-Evers M; Ozmen L; Spooren W
Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Hatori C; Aramori I; Oku T; Tanaka H
J Med Chem; 2004 May; 47(11):2853-63. PubMed ID: 15139763
[TBL] [Abstract][Full Text] [Related]
20. Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.
Giardina GA; Artico M; Cavagnera S; Cerri A; Consolandi E; Gagliardi S; Graziani D; Grugni M; Hay DW; Luttmann MA; Mena R; Raveglia LF; Rigolio R; Sarau HM; Schmidt DB; Zanoni G; Farina C
Farmaco; 1999 Jun; 54(6):364-74. PubMed ID: 10443017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]